<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.biopharminternational.com/view/-immunotherapy-alone-spares-dmmr-rectal-cancer-patients-the-lasting-effects-of-standard-treatment-says-msk-s-andrea-cercek</loc>
      <lastmod>2026-11-20T20:14:47.517Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T20:14:47.517Z</news:publication_date>
        <news:title><![CDATA[Immunotherapy Alone Spares dMMR Rectal Cancer Patients the Lasting Effects of Standard Treatment, Says MSK's Andrea Cercek]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/the-biopharm-brief-long-term-survival-data-for-a-pd-l1-4-1bb-bispecific-celldex-exits-atopic-dermatitis-and-a-fc-fusion-glp-1-goes-global</loc>
      <lastmod>2026-11-19T19:43:58.690Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T19:32:49.937Z</news:publication_date>
        <news:title><![CDATA[The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/leads-biolabs-details-long-term-survival-data-and-2027-adc-combination-plans-for-pd-l1-4-1bb-bispecific-opamtistomig</loc>
      <lastmod>2026-11-20T19:03:31.893Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T19:03:31.893Z</news:publication_date>
        <news:title><![CDATA[Leads Biolabs Details Long-Term Survival Data and 2027 ADC Combination Plans for PD-L1/4-1BB Bispecific Opamtistomig]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/celldex-ends-program-for-its-atopic-dermatitis-treatment-after-phase-2-miss-points-to-limited-role-for-mast-cells</loc>
      <lastmod>2026-11-20T17:35:35.692Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T17:35:35.692Z</news:publication_date>
        <news:title><![CDATA[Celldex Ends Program for its Atopic Dermatitis Treatment After Phase 2 Miss Points to Limited Role for Mast Cells]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/innogen-arcera-licensing-efsubaglutide-alfa-glp-1-international-markets</loc>
      <lastmod>2026-11-20T15:22:49Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T15:22:49Z</news:publication_date>
        <news:title><![CDATA[Innogen Licenses GLP-1 Efsubaglutide Alfa to Arcera in $1 Billion Deal]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.biopharminternational.com/view/merck-sac-tmt-trofuse-015-overall-survival-gastroesophageal-adenocarcinoma</loc>
      <lastmod>2026-11-20T14:57:04Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>BioPharm International</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T14:57:04Z</news:publication_date>
        <news:title><![CDATA[Merck TROP2 ADC Meets Survival End Point in Gastroesophageal Cancer]]></news:title>
      </news:news>
	</url></urlset>